Greenleaf Trust Trims Stock Position in IQVIA Holdings Inc. (NYSE:IQV)

Greenleaf Trust cut its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 3.4% in the 4th quarter, HoldingsChannel.com reports. The fund owned 3,173 shares of the medical research company’s stock after selling 113 shares during the period. Greenleaf Trust’s holdings in IQVIA were worth $624,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in IQV. FMR LLC increased its stake in IQVIA by 38.7% during the third quarter. FMR LLC now owns 2,887,342 shares of the medical research company’s stock worth $684,213,000 after acquiring an additional 804,963 shares during the last quarter. B. Metzler seel. Sohn & Co. Holding AG acquired a new stake in IQVIA during the third quarter worth about $147,683,000. JPMorgan Chase & Co. increased its stake in IQVIA by 46.2% during the third quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock worth $437,378,000 after acquiring an additional 583,396 shares during the last quarter. Nordea Investment Management AB increased its stake in IQVIA by 47.4% during the fourth quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock worth $277,908,000 after acquiring an additional 452,029 shares during the last quarter. Finally, KBC Group NV increased its stake in IQVIA by 68.5% during the fourth quarter. KBC Group NV now owns 616,299 shares of the medical research company’s stock worth $121,109,000 after acquiring an additional 250,458 shares during the last quarter. 89.62% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the company. StockNews.com lowered IQVIA from a “buy” rating to a “hold” rating in a research note on Thursday, November 28th. Stephens assumed coverage on IQVIA in a research note on Friday, December 20th. They issued an “overweight” rating and a $250.00 target price for the company. The Goldman Sachs Group lowered their target price on IQVIA from $280.00 to $250.00 and set a “buy” rating for the company in a research note on Friday, November 1st. Royal Bank of Canada reiterated an “outperform” rating and issued a $270.00 target price on shares of IQVIA in a research note on Wednesday, December 11th. Finally, Truist Financial lowered their target price on IQVIA from $265.00 to $261.00 and set a “buy” rating for the company in a research note on Thursday, December 12th. Five investment analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $254.53.

IQVIA Trading Up 0.4 %

NYSE:IQV opened at $200.00 on Wednesday. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 1.76. The business’s 50 day moving average is $200.31 and its two-hundred day moving average is $220.14. IQVIA Holdings Inc. has a 52 week low of $187.62 and a 52 week high of $261.73. The company has a market cap of $36.30 billion, a PE ratio of 26.25, a P/E/G ratio of 2.15 and a beta of 1.48.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.